



**Ultravist®**  
Iopromide

**medrad®** Centargo  
CT Injection System

# Your Reliable CT Imaging Partner for Seamless Integration

Our team of over 25 experts specializing in customer solutions, clinical experience, medical leadership and technical service has Canada covered from East to West.

**OUR VALUE ADDS UP**  
through connected people and solutions.

CT = computed tomography.



# Compatibility and Comfort Across the CT suite



- The 350 cm single patient line is designed to provide enhanced patient positioning flexibility for CT suites with longer and deeper bores, as well as exams that require greater anatomical coverage.
- The single patient line works efficiently with the MEDRAD® Centargo CT Injection System – **the only multi-patient piston-based CT injector in Canada capable of reaching 300 psi.**

**MEDRAD®** Centargo  
CT Injection System

CT = computed tomography; psi = pounds per square inch.






- ▶ Ultravist®, in combination with the MEDRAD® Centargo Injection System, allows efficiency without compromising patient comfort.
- ▶ A closed system setup limits touch points and the potential for contamination.

**Ultravist®**  
Iopromide

# Optimize Workflow & Enhance Patient Care



Detect air using **seven sensor** and an **automatic air removal procedure**



Automatically **refill reservoirs** and **prime patient lines**



Save up to **23 minutes a day\***

\* Calculations are based on a site that scans on average 30 patients per day, following the values outlined in the PerCent Study.<sup>1</sup>



Stay close to your patient with a **bedside touch screen**




Experience **cordless mobility** with our Wi-Fi connectivity



**Streamline data entry** with the barcode reader



Get ready for the next patient in **less than 20 seconds**



Complete your daily set up in **less than 2 minutes**



**Ultravist**<sup>®</sup>  
Iopromide

**medrad**<sup>®</sup> Centargo  
CT Injection System

# Supporting Consistent Image Quality Across Delivery and Dosing

## Versatility and optimized dosing with SMART Protocols

Centargo is the only injector with a built-in weight-based dosing algorithm with kVp modulation, which automatically adjusts contrast for each patient.



CT angiography showing the curved RCA MPR image and its respective HU values at the proximal and distal segment of the vessel in the 80-90 kg weight category using standard injection protocol (LEFT) and P3T injection protocol (RIGHT).<sup>5</sup> (Adapted from Figure 3 in Jayamani et al., 2024)


Discover real-world examples of the efficiency of SMART Protocols.

Enroll on Radiology Academy



## Versatility and efficiency with Ultravist®

With its low viscosity and low iodine concentration, Ultravist® makes the higher flow rates required for imaging procedures like CTA feasible.<sup>2,3</sup>



Coronary CT Angiography with Ultravist® (iopromide) 370



As demand grows, Ultravist® supply continues to expand, ensuring dependable market availability.

**Ultravist®**  
iopromide

# Real experiences. Real workflow improvements.

*“Our comparison studies\* have shown that we can achieve comparable diagnostic images with a 20 to 30% reduction in contrast dosage using SMART Protocols.”*

*– Mike Minoo, CT Manager, Sunnybrook Health Sciences Centre*

\* Between older generation injectors vs. Centargo.

Learn more  
about our  
CT offerings

#### **Ultravist Indication & Clinical Use:**

ULTRAVIST (iopromide), provided as 300 mg I/mL and 370 mg I/mL, is indicated for:

- Intravascular use to provide diagnostic information in a number of radiographic contrast procedures
- Visualization of various body cavities, e.g., arthrography and hysterosalpingography
- ULTRAVIST 300: computed tomography (CT), excretory urography, pediatric excretory urography, renal arteriography, coronary arteriography (including PTCA) with or without left ventriculography, pediatric angiocardiology, arthrography
- ULTRAVIST 370: computed tomography (CT), excretory urography, coronary arteriography (including PTCA) with or without left ventriculography, pediatric angiocardiology, arthrography
- Differences in safety may be seen in geriatric patients (≥65 years of age)

#### **Contraindications:**

- Myelography, cerebral ventriculography, and cisternography
- Patients with manifest hyperthyroidism
- Intrathecal use
- Preparatory dehydration, including prolonged fasting, restriction of fluids and the administration of a laxative before ULTRAVIST Injection, is contraindicated in pediatric patients because of the risk of renal failure

#### **Other relevant warnings and precautions:**

- Blood clotting
- Serious and fatal reactions
- May obscure lesions seen on prior unenhanced CT scans
- Increased radiation exposure

- Patients with cardiac and circulatory insufficiency, hypertension, pheochromocytoma, cerebral arteriosclerosis, latent hyperthyroidism, severe impairment of hepatic or renal function, pulmonary emphysema, diabetes with renal dysfunction requiring treatment, cerebral arterial spasm, bland nodular goiter, multiple myeloma or other paraproteinemias, and renal transplant
- Risk of thrombosis and embolism with angiography in homocystinuria
- Patients with pronounced states of excitement, anxiety, and pain
- Patients with congestive heart failure receiving concurrent diuretic therapy
- May alter thyroid function, causing hypo- or hyperthyroidism, and may obscure thyroid test results for several weeks after administration
- Patients with sickle cell disease
- Patients undergoing oral cholecystography
- Patients with a history of allergy, sensitivity to iodine/ radiographic media, previous reaction to contrast media, and bronchial asthma
- Hemodynamic disturbances
- Inadvertent injection into an aortic branch or arterial trunk
- Risks of organ damage, nerve injuries, thromboembolic events, and vascular injury during angiographic procedures
- Specialized personnel and monitoring requirements for coronary arteriography and ventriculography
- Patients suspected of having thromboangitis obliterans
- Patients with increased intracranial pressure, disrupted blood-brain barrier or condition that prolongs contrast material in vessels
- Hemorrhage from site of arterial puncture

- Patients with a reduced seizure threshold or neurologic disorders; neurological complications are more frequent in cerebral angiography and related procedures
- Patients with myasthenia gravis
- Patients with renal insufficiency
- Pregnancy and breastfeeding
- Pediatric patients with asthma, sensitivity to medication/ allergens, heart disease, congestive heart failure or serum creatinine > 1.5 mg/dL

#### **For more information:**

Please consult the Product Monograph at <https://www.bayer.com/sites/default/files/2020-11/ultravist-pm-en.pdf> for important information relating to adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling Bayer Medical Information at 1-800-265-7382.

**References:** **1.** Kemper CA, Muhl C, Martens B, et al. Performance of Centargo: A Novel Piston-Based Injection System for High Throughput in CE CT. *Med Devices (Auckl)*. 2022;15:79-87. **2.** Kok M, Muhl C, Hendriks BMF, et al. Patient comfort during contrast media injection in coronary computed tomographic angiography using varying contrast media concentrations and flow rates: results from the EICAR trial. *Invest Radiol*. 2016;51(12):810-815. **3.** Chaya A, Jost G, Endrikat J. Piston-Based vs Peristaltic Pump-Based CT Injector Systems. *Radiol Technol*. 2019 Mar;90(4):344-352. **4.** Ultravist® Product Monograph. Bayer Inc., March 24, 2022. **5.** Jayamani N, Pothiwala S, Ong HB, et al. Clinical audit of the image quality and customised contrast volume using P3T contrast injection software versus standard injection protocol in CT coronary angiography. *Radiography*. 2024;30:1144-1150.



Bayer Inc.  
2920 Matheson Blvd East  
Mississauga (Ontario) L4W 5R6  
Telephone: 800-268-1432  
Fax: 800-567-1710

PP-ULT-CA-0009-1

Bayer reserves the right to modify the specifications and features described herein or to discontinue any product or service identified in this publication at any time without prior notice or obligation. Please contact your authorized Bayer representative for the most current information.

Bayer, the Bayer Cross, MEDRAD, MEDRAD Centargo Injection System, and Ultravist are trademarks owned by and/or registered to Bayer in Canada, the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied.

© 2026 Bayer. This material may not be reproduced, displayed, modified or distributed without the express prior written consent of Bayer.

If you want to report a side effect or quality complaint, please contact your local Health Authority. Reports can also be directed to <https://safetrack-public.bayer.com/>.

Complaints related to Radiology/MEDRAD devices or disposables should be reported to [ricustomercomplaints@bayer.com](mailto:ricustomercomplaints@bayer.com).